Test-retest reliability of tone- and 40 Hz train-evoked gamma oscillations in female rats and their sensitivity to low-dose NMDA channel blockade.
Autorzy:
Raza MU; Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, VA Building 7, Room 324, Maple Ave, Johnson City, TN, 37604, USA. SivaraoDV; Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, VA Building 7, Room 324, Maple Ave, Johnson City, TN, 37604, USA. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2021 Aug; Vol. 238 (8), pp. 2325-2334. Date of Electronic Publication: 2021 May 04.
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
Autorzy:
Bristow LJ; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Easton AE; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Li YW; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. SivaraoDV; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Lidge R; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Jones KM; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Post-Munson D; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Daly C; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Lodge NJ; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Gallagher L; Lead Discovery and Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Molski T; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Pieschl R; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Chen P; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Hendricson A; Lead Discovery and Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Westphal R; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Cook J; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Iwuagwu C; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Morgan D; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Benitex Y; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. King D; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Macor JE; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Zaczek R; Discovery Biology, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America. Olson R; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Jul 28; Vol. 11 (7), pp. e0159996. Date of Electronic Publication: 2016 Jul 28 (Print Publication: 2016).
The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development.
Autorzy:
Keavy D; Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. Bristow LJ; Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. SivaraoDV; Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. Batchelder M; Department of Veterinary Sciences, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. King D; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. Thangathirupathy S; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. Macor JE; Discovery Chemistry, Bristol-Myers Squibb Company, Wallingford, CT, United States of America. Weed MR; Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Company, Wallingford, CT, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Apr 01; Vol. 11 (4), pp. e0152729. Date of Electronic Publication: 2016 Apr 01 (Print Publication: 2016).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
